During the Infection and Immunity symposium 2017, two rounds of workshops will be held, one on Tuesday November 14th and the other on Wednesday November 15th.

On Tuesday 15th of November you will have the opportunity to explore different kind career choices. How do you get a PhD position? Or how do you write a grand proposal? Maybe you are curious about a career in a company?

On Wednesday 15th of November the workshops will cover several in depth I&I-related topics. The specific topics and speakers will follow soon.

Career Workshops will be presented by:

1.Prof. Dr. Jaap Wagenaar, Faculty of Veterinary Medicine, Utrecht University

Prof. Jaap Wagenaar is a professor of Clinical Infectiology. His research looks at how micro-organisms move from animals to humans, as well as the growing resistance of bacteria against
antibiotics. Prof. Wagenaar’s research therefore requires collaboration between veterinary medicine and “human medicine”. The outcomes of Wagenaar’s research will help provide treatments and methods of fighting back against infectious diseases. Additional roles of Prof. Wagenaar include amongst others, serving as a Member of WHO-AGISAR, a consultant for the
FAO, head of the WHO Collaborating Center for Campylobacter, and Member of the Expert Panel of the Veterinary Medicines Agency. His workshop will overview his work both in and outside of academia, and how he ended up in his many current positions.

2. Prof. Dr. C.E. Erik Hack  Laboratory for Translational Immunology (LTI)
Erik Hack (1952) is a Professor of Immunology at the UMCU since 2009. He studied medicine at the University of Amsterdam (the Netherlands) and obtained a MD in 1978, and a PhD in medicine in 1984, from the same university. He was appointed as Professor in Immunology at the Free University Medical Center in 1994. Erik Hack’s research interests are the role of inflammation and coagulation in experimental and human diseases. He has performed a number of clinical and experimental studies on C1-inhibitor in angioedema as well as in other diseases such as sepsis, and amongst others has initiated studies on recombinant C1-inhibitor, which is among the first Dutch biotech products approved by the EMA. His current research is on the modulation of inflammatory and coagulation responses in human disease with antibodies against key mediators, or with so-called synerkines, which are new fusion proteins of cytokines. Erik Hack has co-authored over 500 peer-reviewed papers, which have been cited more than 23,000 times (H-index 81). In addition, he has written >10 patents. Currently he is the head of the LTI, ad hoc consultant to various Biotech companies and and non-executive director of Prothix.


3. Axel Jansen, PhD Candidate, Department of Medical Microbiology, UMC Utrecht

From 2010-2013, I was in the bachelor program Biomedical Sciences at Utrecht University, after which I started the I&I master program in 2013. My first internship was at the Department of Medical Microbiology at the UMC Utrecht under the supervision of Dr. Ir. Willem van Schaik, during which I looked into how colistin resistance can develop in Gram-negative bacteria. My second internship was at the University of California, in San Francisco, in the group of Dr. Jeroen Roose, under supervision of Dr. Yvonne Vercoulen. At UCSF, my topic was Ras-signalling in T- and B-cells. My master thesis was on the potential of genetically engineered oncolytic viruses in cancer-immunotherapy, under supervision of Prof. Dr. Victor van Beusechem, and Prof. Dr. Tanja de Gruijl at the VU Medical Center. After completion of my masters at the end of 2015, I started my PhD in January of 2016, continuing the research from my first internship.

4. Niels Coppens, M.Sc., Medical Science Liaison Immunology, Janssen Pharmeceutical Companies of Johnson & Johnson

Ever wondered what it is like to work for a giant multinational company? What kind of jobs there are and how to get to them? I will take you through some of the important pro’s and con’s of working in the industry and the difference with working in academia. Furthermore, I’ll show you how I ended up were I am now and what my general working week looks like. Also, there will be plenty of time for questions. Hope to see you there!

Scientific Workshops will be presented by:

1.Dr. Mark Shepherd, Senior Lecturer at the School of Biosciences, University of Kent in Canterbury

Targeting bacterial stress responses to combat drug resistance

This workshop will focus on how we can identify vulnerabilities in pathogenic bacteria. There will be a particular focus on nitric oxide tolerance in pathogenic E. coli, and how our understanding of this stress response might lead to new strategies to combat the spread of multidrug-resistant isolates.

2. Prof. Dr. Johanna Fink-Gremmels, Laboratory of Translational Immunology, UMC Utrecht

When Immunology meets Toxicology: the invisible life of fungi

Recent investigations indicated an increasing number of  Aspergillus fumigatus infections in The Netherlands. At the same time, an increase in the prevalence of resistance to common therapeutic agents is observed.  The aim of the workshop is to unravel infection routes, hot spots, and the pathologies related to infections, in toxico-infections and allergies.  

Workshop lay-out (Question- to-concept designs): Short summaries of (review) articles will be used to develop a list of relevant questions that would need to be answered to develop a concept/strategy to combat the risk for fungal infections (here A. fumigatus)  therapy resistance.  

3. Dr. Edward Knol, Laboratory of Translational Immunology, UMC Utrecht

What really makes you itch in eczema

Eczema, also named atopic dermatitis, is very common in the Netherlands affecting 1.6% of the adult and almost 20% of the young infant population. It is an allergic inflammatory disease with the highest IgE level of all allergic diseases. However, treating eczema with a biological against IgE, namely Xolair/Omalizumab/anti-IgE has no clinical benefit. This workshop will deal with the inflammatory response in skin and systemic in eczema. What is the role of local CD8+ T cells, why is treatment with an antibody against IL-4 receptor alpha so successful and what about breaking the strong skin barrier?  

4. Dr. Carla Ribiero, Department of Experimental Immunology, Amsterdam Academic Medical Centre

Dr. Ribeiro is an Assistant Professor and has been awarded a tenure-track position at Academic Medical Centre (AMC). She completed her PhD at Wageningen University, with an International PhD fellowship (Portuguese foundation FCT), and studied innate receptors signalling during parasite infection of the primitive vertebrate carp. In 2011, she moved to AMC and continued working on pathogen sensing mechanisms and established a novel research line on autophagy within the department of Experimental Immunology. Her research line focuses on the identification of host factors and cellular/molecular mechanisms regulating autophagy pathway.  In 2013, dr. Ribeiro was awarded a NWO VENI grant on the function of autophagy and trafficking pathways on HIV-1 infection. She discovered an important role for the autophagy receptor TRIM5α in restricting HIV-1 infection of human Langerhans cells [Ribeiro et al., Nature 2016]. Her innovative approach linking in vivo patient cohort studies and in vitro screening platforms, will provide fundamental knowledge on the causal relationship of autophagy genes and mechanisms to HIV-1 disease progression and chronic inflammatory processes. “



Global Health politicized